Abstract: An information processing apparatus includes a processor that: receives, from a user terminal, a request for first update regarding a first vehicle, notifies the user terminal that the first update is to be performed at a shop, when the first update is update of hardware, and notifies the user terminal that the first update is to be performed through wireless communication, when the first update is update of software.

Abstract: The present invention is directed to methods for the treatment of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steato-hepatitis (NASH) with a phosphodiesterase 4 (PDE4) inhibitor.

Abstract: The present invention is directed to methods for the treatment of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steato-hepatitis (NASH) with a phosphodiesterase 4 (PDE4) inhibitor.

Abstract: The present invention relates to a compound which may be useful as an agent for the prophylaxis or treatment of cancer, hepatitis, hepatic fibrosis, fatty liver and the like.

Abstract: The present invention relates to a compound which may be useful as an agent for the prophylaxis or treatment of cancer, hepatitis, hepatic fibrosis, fatty liver and the like.

Abstract: The present invention provides a compound represented by the formula (I): [wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, p is 0, 1 or 2, and when p is 2, each R may be the same or different, R1 is a hydrogen atom or an optionally substituted hydrocarbon group, R2 is an optionally substituted aromatic group, Ring A is an optionally substituted monocyclic aromatic ring or optionally substituted bicyclic aromatic fused ring, X1 is an oxygen atom or a sulfur atom, X2 is a bond, an oxygen atom or —S(O)n— (wherein n is 0, 1 or 2), Y is a bond, an oxygen atom, —S(O)m—, —C(?O)—N(R3)— or —N(R3)—C(?O)— (R3 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2), M1, M2 and M3 may be the same or different and are each independently a bond or an optionally substituted divalent aliphatic hydrocarbon group, and M4 is an optionally substituted divalent aliphatic hydrocarbon group] or a

Abstract: A preventive/remedy for xanthoma which contains a compound having an inhibitory effect on squalene synthase, its prodrug or its salt.

Abstract: A novel high-density lipoprotein(HDL)-cholesterol level elevating agent containing a compound which has a squalene synthase inhibitory activity.

Abstract: The present invention provides a non-human mammal, or a part of its living body, which stably retains a DNA encoding a heterologous PPAR? in an expressible state, and has one or more different genetic modifications resulting in a pathological condition identical or similar to a disease associated with the regulation of PPAR? activity or a foreign DNA under the control of a promoter having PPRE, as well as a method of screening for agonists/antagonists for the heterologous PPAR? using the animal.

Abstract: The present invention provides a compound represented by the formula (I): [wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, p is 0, 1 or 2, and when p is 2, each R may be the same or different, R1 is a hydrogen atom or an optionally substituted hydrocarbon group, R2 is an optionally substituted aromatic group, Ring A is an optionally substituted monocyclic aromatic ring or optionally substituted bicyclic aromatic fused ring, X1 is an oxygen atom or a sulfur atom, X2 is a bond, an oxygen atom or —S(O)n— (wherein n is 0, 1 or 2), Y is a bond, an oxygen atom, —S(O)m—, —C(?O)—N(R3)— or —N(R3)—C(?O)— (R3 is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and m is 0, 1 or 2), M1, M2 and M3 may be the same or different and are each independently a bond or an optionally substituted divalent aliphatic hydrocarbon group, and M4 is an optionally substituted divalent aliphatic hydrocarbon group] or

Abstract: A novel high-density lipoprotein (HDL)-cholesterol level elevating agent containing a compound which has a squalene synthase inhibitory activity.